Status:
UNKNOWN
Tramadol Clinical Efficiency and Tolerance Correlated to O-desmethyltramadol/Tramadol Ratio (CLINCYTRAM)
Lead Sponsor:
University Hospital, Caen
Conditions:
Pain
Eligibility:
All Genders
18+ years
Brief Summary
Tramadol is a grade II analgesics as World Health Organization definition. It can both be an agonist on mu receptors, which provides it a low opioid action, and also be a Serotonin-norepinephrine reup...
Eligibility Criteria
Inclusion
- Patients \>18 years old treated by tramadol for at least 48h
- Tramadol posology between 100 and 400 mg/d (oral treatment) and until 600 mg/d (veinous treatment), recommended dosage
- Patients with nociceptive pain, definite etiology, combined or not with neuropathic pain
- Caucasian patient
- Patient able to give his/her informed consent
- Patient able to estimate himself/herself pain with pain scale for at least 48h
Exclusion
- Age \< 18 years old
- Patient with chronic pain (\>3 month) or not definite
- Tramadol posology \>400 mg/d (oral treatment) or \> 600 mg/d (veinous treatment)
- Patients with absolute Tramadol contraindication
- Chronic endstage kidney failure antecedent (Cl cockcroft \< 10mL/min) and liver failue antecedent
- Concomitant analgesic treatment, except paracetamol or stopped less than 48h ago
- Pregnant or breast-feeding patient
Key Trial Info
Start Date :
December 1 2016
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
November 1 2018
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT03357003
Start Date
December 1 2016
End Date
November 1 2018
Last Update
November 29 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Caen University Hospital
Caen, France